KING ANDREW JAMES (Head of Renal Discovery) sold 10.9% of their position (2.39K shares) of CHINOOK THERAPEUTICS, INC. on the open market
Open‑market sale worth $56.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/15/2023ACC: 0001209191-23-009766
Officer· Head of Renal Discovery
Since Oct 2020
-2.39K
Net shares
Net seller
$56.8K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
6.80K acquired · 9.20K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+6.80K
Price / share
—
Trade value
—
% of position
45.1%
2/10/2023
15.08K→21.88K
Common Stock
Direct
Shares
−2.39K
Price / share
$23.75
Trade value
$56.81K
% of position
10.9%
2/10/2023
21.88K→19.49K
Total
Net shares
+4.41K
Net value
-$56.81K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/10/2023 | M · Option Exercise | +6.80K | — | — | 45.1% | 15.08K | 21.88K |
| Common Stock Direct | 2/10/2023 | S · Sale | −2.39K | $23.75 | $56.81K | 10.9% | 21.88K | 19.49K |
| Total | +4.41K | -$56.81K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
6.80K shares
Shares
−6.80K
Strike price
Held after
6.80K
Exercisable
—
2/10/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock6.80K shares | 2/10/2023 | M · Option Exercise | −6.80K | — | 6.80K |